Member Info for inanaco

yet Scancell can deliver 20 plus deals of that magnitude with what is available now ... Love it .. wake up AIM

serious missing out on history with your posts Scancell intention in 2009 is to build 5 immunobody not one The science and understanding is not static indeed if we had of just sold scib1 or the platform back in 2013 we would have missed the revolution of change that the check point inhibitors have delivered. so while you guys are working out "ONW Statement" """"resulted in the company becoming a much more difficult to manage entity, which in part explains the gaps that have appeared in its Commercial progression, """" when actually that Gap is the opposite ... its allowed scancell to expand its commercial progression so this is not a negative but a positive ... which is why the SP has been dragged down by lack of understanding around the science rather that the science dragging the sp down. Even Big pharma had made that mistake, dismissing vaccines way to early in the development cycle. They are not saying that now are they !! Always negotiate from a position of strength, and that is exactly what the collaboration with BioNtech delivers and indeed the Combo Immunobody programs. Ie you have the Data so what has this delay given us 2013 Lindy could not turn a cold cancer hot with Moditope, She did not have he means to flip the CD4 to TH1 in other words moditope cd4 would suppress and inflame to maintain a balance which was still significant but not good enough to get to 100% which is what we have today. Also the much "heralded" memory effect ie the re challenge test The reason why that is so important, lindy had to get the vaccine to clear not only solid tumours but stray cancer stem cells that could reseed. Which is one of the reasons we are using 3 epitopes in the vaccine. the memory effect proves that the vaccine killed all cancer stem cells. 2013 Immunobody ...has been improved and gave us the Mark2 versions. Of which the SCIB2 version encompasses that advancement. It gave us all the testing with the PD1 resulting in up coming Combo Trials. So this is not Scancell as "rabbits in headlights" or and other suggestion by ONW like Moditope trumps Immunobody ... as i stated back at the investor day 2013 ......... its Arm Holdings ...

but it does not grant till published ...

ONW, thought you could only claim against patent infringement once the patent was granted. In effect you have only partial protection up to that date, in that you could only threaten to sue. However a party trying to patent Scancells Art would be thwarted by the patent application.

should have said "will grow to $24billion" (currently $10)

coming out ...... "wow" After generating sales of $18.9 billion last year, Humira will turn in $15.23 billion in 2024 sales, according to the analysts' new World Preview 2018, representing a 3% annual slip during the period. Jefferies analysts have predicted sales for the drug will peak at $20.9 billion next year. Humira will still hold pharma's sales crown in that year, according to the report, followed by Merck's Keytruda at $12.69 billion, Celgene's Revlimid at $11.93 billion, Bristol-Myers Squibb's Opdivo at $11.25 billion and BMS and Pfizer's Eliquis at $10.54 billion. All told, worldwide prescription drug sales will reach $1.2 trillion in 2024, according to the group. better revise the potential sales value of Immunobody and moditope ...... as the main PD1 sales have already grown to $24 billion

has to be the bid is higher than the SP

what delayed sell ?

prove the efficacy then do the deal ... key word is efficacy .. as that drives the value

you cannot explain the stock market Ruck ... it once valued scancell at �100m Mcap with nothing like what we have now. was it wrong then and correct today ? or was it right then and wrong today .... how does the "market confirm a valuation ? so the market for a house is easy because you compare to other sells Scancell is easy to ... as we Link directly to PD1 ... if scancell doubles efficacy of the current standard of care, does it not capture that market, and become the standard of care ??? it's not about taking market share, bio is different .. because only the best results become "standard of care" for the majority. i appreciate small cohorts with added complications may fine tune the results, however those are marginal.

you have a clear marker ... if a PD1 or CTl4 works as a stand alone ......... an immunobody can be created to compliment any patient that fails that treatment can receive Moditope plus any cancer that is solid which PD1 fails to show efficacy is a target for Moditope any patient that fails moditope can receive a personal TCR modified T cells specific for there cancer based on the sequencing been done now By Scancell and BioNtech. and any patient at an early stage of cancer can receive a safe vaccination using immunobdy as a stand alone

The global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. https://www.prnewswire.com/news-releases/2018-global-immune-checkpoint-inhibitors-market-outlook-to-2022---opdivo-and-keytruda-presents-significant-growth-opportunity-300601810.html

Panda1 ... for market potential . of immunobody source the current income of the checkpoint inhibitor market PD1 and CTL4 for Moditope, use the entire cancer market ......... as any solid cancer is treatable at late stage.

A deal has finally been done that the market can see value in ... compare it with scancell and its pipeline. all of a sudden ... "wow " look at what they are sitting on .... watch the video folks ... on Scancells website

so what is Modi3 then ONW ......... or have you not noticed that ISA pharma and BioNtech are actually involved in Modi1, i suspect Modi2 and defiantly Modi3 ....... The Grant You understand that money includes funding for trials ? And Lindy Durrant is head of this """ I think it's rather a collaboration between acknowledged experts/ companies for "the Common Good """ what does that mean as clearly it has scientific rational .. I mentioned this many times, but unless your actually quoting facts or can reason a statement, you will get yourself into trouble very quickly ... so why do it ? Just remember this grant has been in the making for over a year, and a lots of science passes scancells desk before we get to see the results, mainly due to risk of Damage to the patents if details are leaked before publication. You may say how is BioNtech involved in Modi1 ... its creating the personalised advanced TCR based on that technology. And i suggest that all important TH1 t cell that lindy has brilliantly configured with the aid of ISA Pharma worth the delay with Moditope ........ absolutely They have not cut corners and the resultant trial data will show that .... which will directly influence inflection points, those of us that understood the value being generated have been helped enormously by the low SP in that all our shares have now moved to Tax Free status under ISA ..... 2012 we thought a �3 payout on sale would be Good, with capital gains tax to pay ....based only on SCIB1 results what is it now ? Break scancell down into components every target is now possible .... and you will not fail to accept that Scancells potential pipeline is mind blowing ......... 1 deal ... then hit the multiple button Tick Tock

i am sure its of Great interest to readers of the Patent Times ... LoL but its of little interest to those that have not understood the Value in that land grab. Once the technology enters the clinic and patients responses analysed. and BioNtech and Roche are excited ... CRUK has put us forward for the Final of the grant award .. based on that technology .... Lot riding on the value of that Patent .. Billions ...

it only grants on publication which is the 13th of june, however its been put out to be published as per RNS Patent Office will grant a European Patent for the Company's Moditope� immunotherapy platform with effect from 13 June 2018.

Only takes one deal .... then multiply the pipeline .... Ouch ! all about the number you hold not the number you don't ... when news breaks. Tick Tock ...

Dramatic treatments prove is this ....... The immune system can deliver a cure. As investors, you have to select the company that is best placed to invent the wheel with out having to design the car first ... This is why that all important science risk analysis / reward of personal portfolios will show up just how good scancell is. It will come

This research has promise for many malignancies,� said Cleveland Clinic medical oncologist Megan Kruse. �We rarely see such deep and durable responses with conventional therapies and we have not seen such dramatic responses with other immunotherapies in breast cancer to date.� But, she cautioned that the time and labor to do such individualized treatments will create �a potential limitation of the approach.� In addition to breast cancer, Dr. Rosenberg has seen regressions in patients with several other types of cancers including bile duct, colon, and cervical cancer. Ms. Perkins arrived at the cancer institute, part of the National Institutes of Health in Bethesda, Md., after multiple chemotherapy and hormonal treatments had failed to stop her cancer from progressing. Cancer institute scientists studied her tumors and identified 62 different mutations in the tumor cells. They then tested her immune cells to evaluate which ones recognized her mutations, then multiplied the immune cells billions of times over and infused them back into her. Her cancer now hasn�t returned, 22 months after treatment. She also received the cancer drug Keytruda, or pembrolizumab, which researchers said was administered to prevent possible inactivation of the infused immune cells. So you have to look at the costs of not only building a personal vaccine but adding a PD1 as well .... Moditope TCR will not need PD1.